Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2023, Vol. 55 ›› Issue (6): 1088-1096. doi: 10.19723/j.issn.1671-167X.2023.06.021

Previous Articles     Next Articles

Clinical and immunological features of primary Sjögren's syndrome patients with positive anti-centromere protein B antibody

Yan-hong MENG1,Yi-fan CHEN2,Pei-ru ZHOU3,*()   

  1. 1. Department of Clinical Laboratory, Peking University School and Hospital of Stomatology & National Center for Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Biomaterials and Digital Medical Devices, Beijing 100081, China
    2. Department of Information Center, Peking University School and Hospital of Stomatology & National Center for Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Biomaterials and Digital Medical Devices, Beijing 100081, China
    3. Department of Oral Medicine, Peking University School and Hospital of Stomatology & National Center for Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Biomaterials and Digital Medical Devices, Beijing 100081, China
  • Received:2022-10-09 Online:2023-12-18 Published:2023-12-11
  • Contact: Pei-ru ZHOU E-mail:zhoupeiru1989@163.com
  • Supported by:
    the Program for New Clinical Techniques and Therapies of Peking University School and Hospital of Stomatology(PKUSSNCT-21B13)

RICH HTML

 1   

PDF (PC)

123

Abstract:

Objective: To investigate the clinical and immunological features of primary Sjögren's syndrome (pSS) patients with positive anti-centromere protein B (CENP-B) antibody. Methods: In this cross-sectional study, the general clinical data, radiographic examination and labial salivary gland biopsy data, and serum immunological and biochemical data of patients diagnosed with pSS from January 2016 to August 2022 were evaluated. The included patients were divided into the anti-CENP-B antibody positive and negative groups. Intergroup differences were analyzed with SPSS 23.0 software. Subgroup analysis was further performed by dividing the anti-CENP-B antibody positive group into the single anti-CENP-B antibody positive and with other auto-antibodies positive groups to determine the characters related to anti-CENP-B antibody. Results: In this study, 288 patients with pSS were evaluated, including 75 patients with anti-CENP-B antibody positive and 213 with anti-CENP-B antibody negative. Univariate analysis showed that compared with the anti-CENP-B antibody negative group, the patients of the anti-CENP-B antibody positive group were older, had lower proportion of the patients with salivary gland enlargement and higher proportion of autoimmune liver disease. As for immunological indicators, the positive proportions of anti-SSA/Ro60, anti-Ro52, and anti-SSB antibodies were significantly lower. Moreover, the immunoglobulin (Ig) G and rheumatoid factor levels were significantly lower, while the IgM level was significantly higher in the patients of the anti-CENP-B antibody positive group. As for serum biochemical indicators, for the patients of the anti-CENP-B antibody positive group, the level of total protein (TP) was lower, the albumin/globulin ratio was higher, and the levels of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), lactate dehydrogenase (LDH) were higher. Subgroup analysis showed that the levels of TP and IgA in the patients of the single anti-CENP-B antibody positive group were significantly lower than those of the patients with other autoantibodies positive group. Conclusion: The pSS patients with anti-CENP-B antibody positive have unique clinical and immunological features of lower disease activity, less likely to involve salivary gland, higher risk for autoimmune liver disease, and higher levels of liver function indicators. Anti-CENP-B antibody may be a marker for a distinct subset of polyautoimmunity in Sjögren's syndrome.

Key words: Centromere protein B antibody, Primary Sjögren's syndrome, Autoantibodies, Immuno-logical features

CLC Number: 

  • R593.2

Figure 1

The flow diagram of screening and grouping of pSS patients pSS, primary Sjögren's syndrome; SGE, salivary gland enlargement; ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; CENP-B, centromere protein B."

Table 1

Comparison of the clinical features of the anti-CENP-B antibody positive and negative pSS patients"

Characteristics Anti-CENP-B antibody (-)(n=213) Anti-CENP-B antibody (+)(n=75) P
Gender, n (%) 0.927
  Male 11 (5.2) 3 (4.0)
  Female 202 (94.8) 72 (96.0)
Age at diagnosis/years, M (P25, P75) 53.0 (38.5, 62.0) 63.0 (54.0, 71.0) < 0.001
Dry mouth symptom duration/months, M (P25, P75) 24 (6, 72) 36 (12, 60) 0.335
UWS ≤0.1 mL/min*, n/total (%) 112/116 (96.6) 42/44 (95.5)
Salivary glands enlargement, n (%) 98 (46.0) 22 (29.3) 0.012
Abnormal conventional X-ray sialography*, n/total (%) 138/151 (91.4) 37/43 (86.0)
LSG biopsy*, n/total (%)
  FLS and FS = 1 foci/4 mm2 10/39 (25.6) 8/33 (24.2)
  FLS and FS = 2 foci/4 mm2 8/39 (20.5) 5/33 (15.2)
  FLS and FS = 3 foci/4 mm2 3/39 (7.7) 4/33 (12.1)
  FLS and FS ≥ 4 foci/4 mm2 18/39 (46.2) 16/33 (48.5)
Dry eyes symptom, n (%) 127 (59.6) 52 (69.3) 0.136
Abnormal Schirmer’s test* or OSS*, n (%) 69 (32.4) 26 (34.7)
Joint involvement, n (%) 41 (19.2) 21 (28.0) 0.113
Hypertension, n (%) 39 (18.3) 15 (20.0) 0.747
Autoimmune liver disease, n (%) 1 (0.5) 4 (5.3) 0.024

Table 2

Comparison of autoantibodies and other immune indicators between groups"

Characteristics Anti-CENP-B antibody (-)(n=213) Anti-CENP-B antibody (+)(n=75) P
Anti-mitochondrial antibody M2, n (%) 12 (5.6) 7 (9.3) 0.401
Anti-ribosomal P-proteins antibody, n (%) 9 (4.2) 3 (4.0) > 0.999
Anti-histones antibody, n (%) 6 (2.8) 1 (1.3) 0.778
Anti-nucleosome antibody, n (%) 3 (1.4) 6 (8.0) 0.015
Anti-dsDNA antibody, n (%) 9 (4.2) 3 (4.0) > 0.999
Anti-PCNA antibody, n (%) 1 (0.5) 0 (0) > 0.999
Anti-Jo-1 antibody, n (%) 5 (2.3) 1 (1.3) 0.953
Anti-PM-Scl antibody, n (%) 5 (2.3) 1 (1.3) 0.953
Anti-Scl-70 antibody, n (%) 3 (1.4) 2 (2.7) 0.839
Anti-SSB antibody, n (%) 108 (50.7) 10 (13.3) < 0.001
Anti-Ro52 antibody, n (%) 178 (83.6) 39 (52.0) < 0.001
Anti-SSA/Ro60 antibody, n (%) 190 (89.2) 36 (48.0) < 0.001
Anti-Sm antibody, n (%) 4 (1.9) 4 (5.3) 0.247
Anti-nRNP/Sm antibody, n (%) 17 (8.0) 3 (4.0) 0.243
IgG/(g/L), M (P25, P75) 19.55 (16.24, 24.73) 17.90 (13.51, 19.12) < 0.001
IgA/(g/L), M (P25, P75) 2.91 (2.33, 3.65) 2.91 (2.03, 3.50) 0.154
IgM/(g/L), M (P25, P75) 1.34 (0.92, 1.65) 1.34 (1.07, 2.42) 0.017
C3/(g/L), ${\bar x}$±s 1.313±0.238 1.310±0.227 0.074
RF/(g/L), M (P25, P75) 30.47 (19.30, 105.89) 18.20 (5.55, 30.42) < 0.001

Table 3

Multivariate analysis of anti-CENP-B antibody and immunoglobulins by binary Logistic regression"

Items P value OR (95% CI)
IgG* < 0.001 0.897 (0.850-0.947)
IgM* 0.007 1.321 (1.079-1.618)

Table 4

Comparison of serum biochemical indexes between groups"

Characteristics Anti-CENP-B antibody (-) (n=213) Anti-CENP-B antibody (+) (n=75) P
TP/(g/L), M (P25, P75) 80.0 (75.7, 84.0) 75.0 (72.0, 81.0) < 0.001
Alb/(g/L), M (P25, P75) 43.7 (41.7, 46.0) 44.0 (42.3, 46.0) 0.372
A/G, ${\bar x}$±s 1.240±0.270 1.410±0.266 < 0.001
ALT/(U/L), M (P25, P75) 16.0 (12.0, 21.8) 19.5 (14.0, 28.0) 0.014
AST/(U/L), M (P25, P75) 20.0 (17.0, 26.0) 24.0 (19.0, 31.0) 0.001
AST/ALT, M (P25, P75) 1.29 (1.00, 1.61) 1.31 (1.09, 1.45) 0.089
TBIL/(μmol/L), M (P25, P75) 12.08 (9.80, 15.87) 12.54 (10.10, 15.01) 0.777
DBIL/(μmol/L) M (P25, P75) 2.91 (2.26, 3.80) 3.20 (2.47, 4.05) 0.188
ALP/(U/L), M (P25, P75) 73.0 (67.0, 80.0) 73.0 (70.0, 99.0) 0.034
GGT/(U/L), M (P25, P75) 18.0 (14.9, 20.0) 18.0 (14.0, 35.0) 0.046
CK/(U/L), M (P25, P75) 64.0 (55.0, 73.5) 64.0 (52.0, 81.0) 0.652
LDH/(U/L), M (P25, P75) 171.0 (152.5, 175.0) 171.0 (171.0, 194.0) < 0.001

Table 5

Subgroup analysis according to the positive status of anti-CENP-B antibody and other autoantibodies"

Characteristics Anti-CENP-B antibody (+) alone(n=24) Anti-CENP-B and other autoantibodies (+)(n=51) P
IgA/(g/L), M (P25, P75) 2.11 (1.78, 2.91) 2.91 (2.24, 3.74) 0.027
TP/(g/L), M (P25, P75) 72.6 (69.2, 76.5) 76.6 (73.0, 82.0) 0.032
1 Mavragani CP , Moutsopoulos HM . Sjögren syndrome[J]. CMAJ, 2014, 186 (15): E579- E586.
doi: 10.1503/cmaj.122037
2 Stefanski AL , Tomiak C , Pleyer U , et al. The diagnosis and treatment of Sjögren's syndrome[J]. Dtsch Arztebl Int, 2017, 114 (20): 354- 361.
3 Shiboski CH , Shiboski SC , Seror R , et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for primary Sjögren's syndrome: A consensus and data-driven methodology involving three international patient cohorts[J]. Arthritis Rheumatol, 2017, 69 (1): 35- 45.
doi: 10.1002/art.39859
4 Yoda K , Kitagawa K , Masumoto H , et al. A human centromere protein, CENP-B, has a DNA binding domain containing four potential alpha helices at the NH2 terminus, which is separable from dimerizing activity[J]. J Cell Biol, 1992, 119 (6): 1413- 1427.
doi: 10.1083/jcb.119.6.1413
5 Tanaka Y , Nureki O , Kurumizaka H , et al. Crystal structure of the CENP-B protein-DNA complex: The DNA-binding domains of CENP-B induce kinks in the CENP-B box DNA[J]. EMBO J, 2001, 20 (23): 6612- 6618.
doi: 10.1093/emboj/20.23.6612
6 Baer AN , Medrano L , McAdams-DeMarco M , et al. Association of anticentromere antibodies with more severe exocrine glandular dysfunction in Sjögren's syndrome: Analysis of the Sjögren's International Collaborative clinical alliance cohort[J]. Arthritis Care Res (Hoboken), 2016, 68 (10): 1554- 1559.
doi: 10.1002/acr.22859
7 Tsukamoto M , Suzuki K , Takeuchi T . Clinical and immunological features of anti-centromere antibody-positive primary Sjögren's syndrome[J]. Rheumatol Ther, 2018, 5 (2): 499- 505.
doi: 10.1007/s40744-018-0126-2
8 Nakamura H , Morimoto S , Shimizu T , et al. Clinical manifestations in anti-Ro52/SS-A antibody-seropositive patients with Sjögren's syndrome[J]. Immunol Med, 2021, 44 (4): 252- 262.
doi: 10.1080/25785826.2021.1919342
9 Lee YJ . Is the anti-centromere antibody a marker for a distinct subset of polyautoimmunity in Sjögren's syndrome?[J]. Korean J Intern Med, 2021, 36 (6): 1323- 1326.
doi: 10.3904/kjim.2021.467
10 中华医学会肝病学分会. 自身免疫性肝炎诊断和治疗指南(2021)[J]. 中华内科杂志, 2021, 60 (12): 1038- 1049.
doi: 10.3760/cma.j.cn112138-20211112-00796
11 中华医学会肝病学分会. 原发性胆汁性胆管炎的诊断和治疗指南(2021)[J]. 中华内科杂志, 2021, 60 (12): 1024- 1037.
doi: 10.3760/cma.j.cn112138-20211112-00794
12 中华医学会肝病学分会. 原发性硬化性胆管炎诊断及治疗指南(2021)[J]. 中华内科杂志, 2021, 60 (12): 1050- 1074.
doi: 10.3760/cma.j.cn112138-20211109-00786
13 Rubin P , Holt JF . Secretory sialography in diseases of the major salivary glands[J]. Am J Roentgenol Radium Ther Nucl Med, 1957, 77 (4): 575- 598.
14 Sun Z , Zhang Z , Fu K , et al. Diagnostic accuracy of parotid CT for identifying Sjögren's syndrome[J]. Eur J Radiol, 2012, 81 (10): 2702- 2709.
doi: 10.1016/j.ejrad.2011.12.034
15 Gamba R , Fachinetti D . From evolution to function: Two sides of the same CENP-B coin?[J]. Exp Cell Res, 2020, 390 (2): 111959.
doi: 10.1016/j.yexcr.2020.111959
16 Gelber AC , Pillemer SR , Baum BJ , et al. Distinct recognition of antibodies to centromere proteins in primary Sjögren's syndrome compared with limited scleroderma[J]. Ann Rheum Dis, 2006, 65 (8): 1028- 1032.
doi: 10.1136/ard.2005.046003
17 史洪博, 吕俊楠. 抗着丝点抗体阳性的原发干燥综合征临床及实验室特征分析[J]. 医学研究生学报, 2020, 33 (8): 839- 843.
doi: 10.16571/j.cnki.1008-8199.2020.08.011
18 颜淑敏, 曾小峰, 赵岩, 等. 抗着丝点抗体阳性原发性干燥综合征的临床特点[J]. 中华内科杂志, 2008, 47 (4): 296- 299.
doi: 10.3321/j.issn:0578-1426.2008.04.011
19 Min HK , Kim SH , Park Y , et al. Ultrasonographic characteristics of major salivary glands in anti-centromere antibody-positive primary Sjögren's syndrome[J]. PLoS One, 2021, 16 (11): e0259519.
doi: 10.1371/journal.pone.0259519
20 Lee KE , Kang JH , Lee JW , et al. Anti-centromere antibody-positive Sjögren's syndrome: A distinct clinical subgroup?[J]. Int J Rheum Dis, 2015, 18 (7): 776- 782.
doi: 10.1111/1756-185X.12684
21 Kajio N , Takeshita M , Suzuki K , et al. Anti-centromere antibo-dies target centromere-kinetochore macrocomplex: A comprehensive autoantigen profiling[J]. Ann Rheum Dis, 2021, 80 (5): 651- 659.
doi: 10.1136/annrheumdis-2020-218881
22 Seror R , Ravaud P , Bowman SJ , et al. EULAR Sjögren's syndrome disease activity index: Development of a consensus systemic disease activity index for primary Sjögren's syndrome[J]. Ann Rheum Dis, 2010, 69 (6): 1103- 1109.
doi: 10.1136/ard.2009.110619
23 Li Y , Bookman AAM . Comparison of effect on sicca symptoms of anticentromere antibody-positive Sjögren's syndrome and primary Sjögren's syndrome alone[J]. J Rheumatol, 2020, 47 (6): 876- 880.
doi: 10.3899/jrheum.190462
24 Miyawaki S , Asanuma H , Nishiyama S , et al. Clinical and serological heterogeneity in patients with anticentromere antibodies[J]. J Rheumatol, 2005, 32 (8): 1488- 1494.
25 包振英, 彭科凤, 孟彦宏, 等. 抗着丝点蛋白B抗体阳性的原发性干燥综合征的实验室特征分析[J]. 中国预防医学杂志, 2018, 19 (3): 234- 237.
doi: 10.16506/j.1009-6639.2018.03.011
26 Park Y , Lee J , Koh JH , et al. Clinical influences of anticentromere antibody on primary Sjögren's syndrome in a prospective Korean cohort[J]. Korean J Intern Med, 2021, 36 (6): 1492- 1503.
doi: 10.3904/kjim.2020.146
27 Suzuki Y , Fujii H , Nomura H , et al. Impact of double positive for anti-centromere and anti-SS-a/Ro antibodies on clinicopathological characteristics of primary Sjögren's syndrome: A retrospective cohort study[J]. Mod rheumatol, 2018, 28 (5): 872- 878.
doi: 10.1080/14397595.2017.1418164
[1] Xiao-yan XING,Jun-xiao ZHANG,Feng-yun-zhi ZHU,Yi-fan WANG,Xin-yao ZHOU,Yu-hui LI. Clinical analysis of 5 cases of dermatomyositis complicated with macrophage activation syndrome [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1214-1218.
[2] Lu ZHANG,Cheng CHEN,Mei-ting WENG,Ai-ping ZHENG,Mei-ling SU,Qing-wen WANG,Yue-ming CAI. Characteristics of serum autoantibodies in patients with lupus nephritis and tubulointerstitial damage [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1094-1098.
[3] XIAO Yun-shu,ZHU Feng-yun-zhi,LUO Lan,XING Xiao-yan,LI Yu-hui,ZHANG Xue-wu,SHEN Dan-hua. Clinical and immunological characteristics of 88 cases of overlap myositis [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1088-1093.
[4] LUO Lan,XING Xiao-yan,XIAO Yun-shu,CHEN Ke-yan,ZHU Feng-yun-zhi,ZHANG Xue-wu,LI Yu-hui. Clinical and immunological characteristics of patients with anti-synthetase syndrome complicated with cardiac involvement [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1078-1082.
[5] Jing ZHAO,Feng SUN,Yun LI,Xiao-zhen ZHAO,Dan XU,Ying-ni LI,Yu-hui LI,Xiao-lin SUN. Significance of anti-tubulin-α-1C autoantibody in systemic sclerosis [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1009-1013.
[6] Feng-yun-zhi ZHU,Xiao-yan XING,Xiao-fei TANG,Yi-min LI,Miao SHAO,Xue-Wu ZHANG,Yu-hui LI,Xiao-lin SUN,Jing HE. Clinical and immunological characteristics of myositis complicated with thromboembolism [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 995-1000.
[7] Yi-ming ZHENG,Hong-jun HAO,Yi-lin LIU,Jing GUO,Ya-wen ZHAO,Wei ZHANG,Yun YUAN. Correlation study on anti-Ro52 antibodies frequently co-occur with other myositis-specific and myositis-associated autoantibodies [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1088-1092.
[8] XU Jing, LIU Jing,ZHU Lei, ZHANG Xue-wu, LI Zhan-guo. Significance of glucose-6-phosphate isomerase assay in early diagnosis of rheumatoid arthritis [J]. Journal of Peking University(Health Sciences), 2016, 48(6): 942-946.
[9] WANG Lin-Lin, YANG Na, YUAN Yue, REN Ai-Guo. Establishment and evaluation of enzyme-linked immunosorbent assay for measuring human autoantibody IgG to folate receptor [J]. Journal of Peking University(Health Sciences), 2014, 46(3): 483-487.
[10] LIU Yuan, WANG Yong-Fu, WANG Kai-Li, 吕Feng-Feng . Prevalence and significance of immunoglobulin G-anti-cyclic citrullinated peptide antibodies in primary Sjögren’s syndrome patients [J]. Journal of Peking University(Health Sciences), 2014, 46(3): 478-482.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd